Hepatitis C treatment side-effects

Hepatitis C treatment side-effects features

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:  HIV treatment update

Hepatitis C treatment side-effects in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From: In your own words

Hepatitis C treatment side-effects news from aidsmap

• Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe

  “Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C virus (HCV) co-infection who receive treatment, according to research presented at ...

  19 April 2018 | Michael Carter

• Viral suppression protects against long-term liver damage caused by older HIV drugs

  A history of treatment with some older antiretroviral drugs can have a lasting negative impact on liver health, German researchers report in PLOS One. They found that although co-infection with hepatitis C virus (HCV) was the ...

  29 January 2018 | Michael Carter

• D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

  Long-term therapy with the antiretroviral drug tenofovir increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published in the online edition of AIDS. Five-year cumulative use of the ...

  21 January 2016 | Michael Carter

• Abacavir/lamivudine could be driving liver damage in ART-treated patients with HIV/HCV co-infection

  Progression of liver fibrosis among ART-treated patients with HIV/HCV co-infection is associated with the type of nucleoside reverse transcriptase inhibitor (NRTI) “backbone”, Canadian research published in the online edition of Clinical Infectious Diseases suggests. The study was designed to see ...

  14 October 2015 | Michael Carter

• Sustained response to treatment reduces fatigue in hepatitis C patients

  Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according to research presented at the 49th annual meeting of the European ...

  06 May 2014 | Liz Highleyman

• Merck combination suppresses HCV in mono-infected and co-infected patients

  An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people with HIV and HCV co-infection and high cure rates for people with ...

  21 March 2014 | Liz Highleyman

• Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

  The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus (HCV) and HIV co-infection in the STARTVerso4 trial, equaling response rates for ...

  05 March 2014 | Liz Highleyman

• Six-week oral treatment can cure hard-to-treat hepatitis C patients

  Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1 hepatitis C virus (HCV), including those with traditional predictors of poor response, ...

  04 March 2014 | Liz Highleyman

• Low lymphocyte count a risk factor for infections for people taking HCV therapy

  A low lymphocyte count is associated with an increased risk of infections during hepatitis C virus (HCV) treatment that includes pegylated interferon and ribavirin, according to the results of a large observational study published in the online edition of ...

  16 January 2014 | Michael Carter

• Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection

  The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a report at the 14th European AIDS ...

  22 October 2013 | Liz Highleyman

More news

Hepatitis C treatment side-effects news selected from other sources

• Optimism About HCV Treatment Comes With Caveats

  Despite significant advances in treatment for individuals with HCV infection, several important issues prevail in this patient population.

  22 March 2017 | Medscape

• Are New Drugs for Hepatitis C Safe? A Report Raises Concerns

  Drugs approved in recent years that can cure hepatitis C may have severe side effects, including liver failure, a new report suggests. The number of adverse events appears relatively small, and the findings are not conclusive. But experts said the report was a warning that should not be ignored.

  25 January 2017 | New York Times

• HCV Drugs May Reactivate HBV, FDA Warns

  Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

  06 October 2016 | Medscape (free registration required)

• Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy

  Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone.

  29 June 2015 | HIVandHepatitis.com

• Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

  Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.

  14 October 2013 | Healio Hepatology

• Depression in HCV Often Resolves After Interferon Treatment

  Depression affects up to 50% of patients with chronic hepatitis C virus (HCV) infection receiving treatment with interferon, but it appears to be self-limiting and does not usually require antidepressant therapy, new research suggests.

  12 April 2013 | Medscape (requires registration)

• Health Canada Warns Of Serious Skin Reactions From Hepatitis C Drug

  Two months after the FDA issued a safety alert informing about the serious skin reactions, some fatal, in patients taking Vertex Pharmaceuticals Inc.'s (VRTX: Quote) hepatitis C drug Incivek (telaprevir), it is now health Canada's turn to alert health-care providers and patients.

  01 March 2013 | RTT News

• Hepatitis C Model Delivers Great Care Anywhere

  Optimal HCV treatment for patients in a comprehensive health system requires an efficient and effective process. Ideally, the established structure would support rural as well as urban settings and allow for sharing of information, education of providers, and metrics to monitor treatments. Such a process was established successfully within the Department of VA.

  25 February 2013 | Infectious Disease Special Edition

• Copy of Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

  A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

  15 February 2013 | CATIE

• Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

  A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

  15 February 2013 | CATIE

More news